| A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer (NCT07545044) | Shanghai JMT-Bio Inc. | 2026-05-30 |
| A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer (NCT07441460) | Shanghai JMT-Bio Inc. | 2026-03-06 |
| SYS6090 Combination Therapy in Advanced Lung Cancer (NCT07472647) | Shanghai JMT-Bio Inc. | 2026-02-28 |
| JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan (NCT07384377) | Shanghai JMT-Bio Inc. | 2026-02-06 |
| Evaluate the Safety, Tolerability, PK, and PD of JMT206 Injection in Healthy Participants (NCT07419698) | Shanghai JMT-Bio Inc. | 2026-01-26 |
| A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer (NCT07332533) | Shanghai JMT-Bio Inc. | 2025-12-30 |
| Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors (NCT07280832) | Shanghai JMT-Bio Inc. | 2025-12-17 |
| The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer (NCT07134205) | Shanghai JMT-Bio Inc. | 2025-10-01 |
| JMT106 Injection in the Treatment of Advanced Solid Tumors (NCT07275073) | Shanghai JMT-Bio Inc. | 2025-09-25 |
| a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia (NCT07140809) | Shanghai JMT-Bio Inc. | 2025-09-09 |
| A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy (NCT07029139) | Shanghai JMT-Bio Inc. | 2025-06-30 |
| JSKN003 Combined Treatment of HER2-positive Gastric Cancer (NCT06998771) | Shanghai JMT-Bio Inc. | 2025-06-15 |
| Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients (NCT06908772) | Shanghai JMT-Bio Inc. | 2025-04-01 |
| JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer (NCT06892431) | Shanghai JMT-Bio Inc. | 2025-04-01 |
| JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer (NCT06846437) | Shanghai JMT-Bio Inc. | 2025-02-18 |
| A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer (NCT06747338) | Shanghai JMT-Bio Inc. | 2024-12-16 |
| A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations (NCT06735391) | Shanghai JMT-Bio Inc. | 2024-10-23 |
| A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JMT202 (NCT06564467) | Shanghai JMT-Bio Inc. | 2024-07-23 |
| A Study of JMT203 in Patients With Cancer Cachexia (NCT06868849) | Shanghai JMT-Bio Inc. | 2024-05-15 |
| Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer (NCT06319313) | Shanghai JMT-Bio Inc. | 2024-05-01 |
| JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations (NCT06380348) | Shanghai JMT-Bio Inc. | 2024-04-26 |
| A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid (NCT06221072) | Shanghai JMT-Bio Inc. | 2024-04-05 |
| A Study of JMT101 in Patients With Metastatic Colorectal Cancer (NCT06089330) | Shanghai JMT-Bio Inc. | 2024-01-01 |
| Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer. (NCT05838066) | Shanghai JMT-Bio Inc. | 2023-07-23 |
| A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone (NCT05813665) | Shanghai JMT-Bio Inc. | 2023-04-01 |
| Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer (NCT05513664) | Shanghai JMT-Bio Inc. | 2022-09-01 |
| Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis (NCT05397938) | Shanghai JMT-Bio Inc. | 2022-06-15 |
| Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis (NCT05278338) | Shanghai JMT-Bio Inc. | 2022-04-21 |
| KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy (NCT05427383) | Shanghai JMT-Bio Inc. | 2022-04-07 |
| JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations (NCT06391944) | Shanghai JMT-Bio Inc. | 2021-11-21 |
| Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer (NCT05132777) | Shanghai JMT-Bio Inc. | 2021-11-20 |
| A Real-world Study on Patients of Unresectable Giant Cell Tumor of Bone (NCT05402865) | Shanghai JMT-Bio Inc. | 2021-11-10 |
| A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma (NCT06725524) | Shanghai JMT-Bio Inc. | 2021-10-12 |
| Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors (NCT04630522) | Shanghai JMT-Bio Inc. | 2020-10-31 |
| Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer (NCT04448379) | Shanghai JMT-Bio Inc. | 2020-06-29 |
| A Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory HCM (NCT04198480) | Shanghai JMT-Bio Inc. | 2020-01-24 |
| Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone (NCT04255576) | Shanghai JMT-Bio Inc. | 2019-10-10 |
| Safety, Tolerability and PK/PD of JMT103 in Patients With Bone Metastases From Tumors (NCT03550508) | Shanghai JMT-Bio Inc. | 2018-05-21 |